FURUNO-ELECTRIC
20.8.2024 06:01:33 CEST | Business Wire | Press release
Furuno Electric is delighted to announce that the company will participate in Jammertest 2024 in Andøya, Norway from 9 to 13 September.
The participants will test GNSS receivers in an environment where they will actually be exposed to jamming and spoofing* signals and obtain data on their tolerance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240819796325/en/
Jammertest 2024 (Graphic: Business Wire)
About Jammertest
This Jammertest is the world's largest test event where resistance to jamming and spoofing can be tested in a real environment. It is organized by the Norwegian Public Roads Administration, Norwegian Communications Authority, Norwegian Defence Research Establishment, Norwegian Metrology Service, Norwegian Space Agency and Testnor.
Jamming has actually been detected in the Black Sea, Northern Europe, and the Middle East, and there is a growing need for enhanced resiliency in critical infrastructure such as traffic control and mobile communications. Furuno has been testing its receivers by creating signals that simulate jamming and spoofing in a lab environment, but to verify and improve our anti-jamming capabilities, it is ideal to perform a variety of evaluations in a real environment. To allow participating companies and institutions to test their GNSS receiver-equipped products in a real-world environment, the organizer will conduct various types of jamming and spoofing attacks during the event.
The resistance test Furuno will carry out
In this Jammertest, Furuno will test the jamming and spoofing resistance of GT-100 which is Furuno’s timing multi-GNSS receiver module that supports dual-frequency band reception in the L1 and L5 bands. GNSS receivers for time synchronization are used in critical infrastructures that require robustness, such as 5G mobile base stations, TV broadcasting, financial institutions, and power grids. The latest product, GT-100, can automatically mitigate the effects of jamming and spoofing signals while providing users with real-time notification of the jamming signal frequency and signal strength. Also, if it completely loses reception of the L1 band signal, it can still maintain reception of the L5 band signal and continuously output stable time.
By participating in the Jammertest 2024, Furuno will evaluate and analyze the level of resistance of GT-100 to jamming and spoofing in real-world environments and use the results to further improve its robustness.
About Jammertest 2024
Official name of the event: Jammertest 2024
Event dates: September 9 - 13, 2024
Location: Andøya, Norway
Official website: https://jammertest.no/jammertest/
Products Tested
Timing Multi-GNSS Receiver Module GT-100
https://www.furuno.com/en/products/gnss-module/GT-100
Multi-GNSS Timing Antennas AU-500
https://www.furuno.com/en/products/gnss-antenna/AU-500
* Jamming and Spoofing: Jamming means radio waves that interfere with GNSS signals. Spoofing means that malicious actors intentionally mimic and broadcast GNSS-like signals with the intent to trick nearby GNSS receivers into calculating incorrect position and/or time.
Related Links
Announced on May 16, 2023: Furuno Announces High-Performance Multi-GNSS Timing Antennas
https://www.furuno.co.jp/en/news/general/general_category.html?itemid=1320&dispmid=961
Announced on September 14, 2022: Furuno Announces Most Advanced Global Timing Solutions Supporting L1 and L5 GNSS Signals
https://www.furuno.co.jp/en/news/general/general_category.html?itemid=1216&dispmid=961
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240819796325/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom